Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.
Our novel product pipeline addresses areas of high unmet medical need, with a focus on epilepsy.
UPCOMING EVENT: Xenon will host its Annual Meeting of Shareholders on June 1, 2023 at 2:30 PM EDT. Read more…
Read MoreNews
Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 11, 2023
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 9, 2023
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023
May 3, 2023
Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting
April 24, 2023
Product Pipeline
XEN1101
for Focal Onset Seizures (FOS)
X-TOLE2/3 Clinical Trial
XEN1101
for Primary Generalized Tonic-Clonic Seizures (PGTCS)
X-ACKT Clinical Trial
XEN1101
for Major Depressive Disorder (MDD)
X-NOVA Clinical trial
XEN1101
for MDD
Investigator-led Phase 2 POC study Collaboration with Mount Sinai
NBI-921352
for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences
NBI-921352
for Focal-Onset Seizures in Adults
Partnered with Neurocrine Biosciences
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
